ALTIMMUNE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Altimmune, Inc. and Encourages Investors to Contact the Firm
Altimmune, Inc. (ALT)
NASDAQ:AMEX Investor Relations:
altimmune.com/investors
Company Research
Source: GlobeNewswire
NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) in the United States District Court for the District of Maryland on behalf of all persons and entities who purchased or otherwise acquired Altimmune securities between December 1, 2023 and April 26, 2024, both dates inclusive (the “Class Period”). Investors have until July 5, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here to participate in the action. Altimmune is a clinical stage biopharmaceutical company that focuses on developing treatments for obesity and liver diseases. The Company's lead product candidate is pemvidutide, a glucagon-like peptide-1 (“GLP-1”) agonist for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (“MASH”). GLP-1 agonists are medica
Show less
Read more
Impact Snapshot
Event Time:
ALT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALT alerts
High impacting Altimmune, Inc. news events
Weekly update
A roundup of the hottest topics
ALT
News
- Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALTAccesswire
- Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 5, 2024 - ALTAccesswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALTAccesswire
- Altimmune, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALTAccesswire
- Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALTAccesswire
ALT
Earnings
- 5/9/24 - Beat
ALT
Sec Filings
- 7/1/24 - Form 3
- 6/26/24 - Form 8-K
- 5/9/24 - Form 10-Q
- ALT's page on the SEC website